Table 4 Distribution of CYP3 genotypes and risk of neoadjuvant chemotherapy resistance developing in breast cancer patients
Polymorphism | Genotype | Positive neoadjuvant chemotherapy response | Negative neoadjuvant chemotherapy response | OR | CI (95%) | p | ||
|---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
CYP3A4*1B A-392 G | AA | 234 | 94.74 | 9 | 90.00 | 0.04 | 0.01 - 3.47 | 0.08 |
AG | 13 | 5.26 | 1 | 10.00 | 24.90 | 0.29 - 1961.25 | 0.08 | |
GG | 0 | 0.00 | 0 | 0.00 | * | |||
CYP3A4*2 T664C | TT | 249 | 100.00 | 10 | 100.00 | * | ||
TC | 0 | 0.00 | 0 | 0.00 | * | |||
CC | 0 | 0.00 | 0 | 0.00 | * | |||
CYP3A5*3 A6986G | AA | 0 | 0.00 | 0 | 0.00 | * | ||
AG | 33 | 13.31 | 1 | 10.00 | 0.72 | 0.02 - 5.53 | 0.99 | |
GG | 215 | 86.69 | 9 | 90.00 | 1.38 | 0.18 - 62.36 | 0.99 | |